News from rxi pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 14, 2018, 07:10 ET RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Nov 07, 2018, 07:05 ET RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Nov 06, 2018, 07:05 ET RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Oct 03, 2018, 16:31 ET RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Oct 01, 2018, 06:10 ET RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Sep 26, 2018, 08:00 ET RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 28, 2018, 09:15 ET RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 15, 2018, 09:25 ET RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 14, 2018, 09:15 ET RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 07, 2018, 07:15 ET RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 02, 2018, 09:25 ET RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Aug 01, 2018, 09:25 ET RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


May 18, 2018, 11:58 ET RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


May 11, 2018, 07:05 ET RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors

RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it has entered into a research collaboration with Iovance Biotherapeutics to...


May 10, 2018, 07:05 ET RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


May 08, 2018, 02:20 ET RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


May 01, 2018, 07:05 ET RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Apr 16, 2018, 11:25 ET RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...


Apr 09, 2018, 02:04 ET RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing immuno-oncology therapeutics based on its proprietary...


Apr 04, 2018, 07:05 ET RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference

RXi Pharmaceuticals Corporation, a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi...


Mar 26, 2018, 04:40 ET RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary...


Mar 21, 2018, 01:00 ET RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary...


Mar 20, 2018, 07:05 ET RXi Pharmaceuticals Selected to Present at the Landmark Venture Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary...


Feb 05, 2018, 07:05 ET RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi...


Jan 17, 2018, 07:05 ET RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced that it...